Eiko Lifesciences has formally disputed recovery proceedings launched by IDBI Bank Limited regarding a historical corporate guarantee. The dispute centers on an alleged guarantee of ₹58 lakhs purportedly issued in 1986 by the company’s erstwhile entity, Narendra Investments (Delhi) Limited. The guarantee was linked to financial facilities extended to Consolidated Steels & Alloys Limited.

The matter relates to a transaction dating back nearly four decades. According to documents provided by IDBI Bank, the alleged guarantee remains outstanding, prompting the bank to initiate recovery actions against Eiko Lifesciences. The company has neither admitted nor acknowledged any liability in relation to this claim.

Legal Position and Management View

Eiko Lifesciences stated that it has taken appropriate legal steps and is actively pursuing all available remedies before the relevant authorities. The management maintains that based on the facts currently available and the legal position being pursued, the matter is not expected to have any material financial impact on the company or its ongoing business operations.

The company disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It indicated that it will continue to monitor the situation and make further disclosures as required by applicable laws and regulations.

Eiko Lifesciences Limited reported a 34.98% year-on-year increase in consolidated net profit to ₹150.83 lakh for the quarter ended June 30, 2026 (Q1FY27). The Mumbai-based speciality chemicals company saw revenue from operations surge 56.36% YoY to ₹1,715.96 lakh, driven by robust demand in its core chemical business and expanding logistics operations. This growth trajectory signals strengthening operational efficiency despite rising material costs.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors PSV Jain & Associates. The company operates under a single business segment for standalone reporting but discloses two reportable segments—Speciality & Fine Chemicals and Logistics Services—in its consolidated statements.

Financial Performance Highlights

Consolidated revenue from operations rose to ₹1,715.96 lakh in Q1FY27, compared to ₹1,097.66 lakh in the same period last year. Standalone revenue also climbed significantly to ₹1,486.51 lakh from ₹800.60 lakh YoY. Total comprehensive income for the group stood at ₹150.83 lakh, up from ₹111.74 lakh in Q1FY26.

*Profit before exceptional items, share of profit in equity accounted investees, and tax for consolidated; Profit before exceptional items and tax for standalone.

Segment-Wise Breakdown

The Speciality & Fine Chemicals segment contributed ₹15.25.32 lakh to consolidated revenue, up from ₹8.40.22 lakh YoY, with segment results improving to ₹98.86 lakh from ₹44.42 lakh. The Logistics Services segment, operated through subsidiary Eikovivify Logistics Private Limited, generated ₹1.49.56 lakh in revenue, down slightly from ₹2.30.93 lakh YoY, but maintained stable segment results of ₹28.67 lakh.

Cost of materials consumed accounted for the largest expense head at ₹13.93.79 lakh (consolidated), reflecting higher input prices. However, favorable changes in inventories of finished stock and work-in-progress (-₹40.96 lakh) helped offset some cost pressures. Finance costs increased to ₹13.01 lakh from ₹4.82 lakh YoY, primarily due to higher borrowing levels supporting operational expansion.

What the Numbers Show

The divergence between standalone and consolidated growth rates reveals the impact of associate companies and subsidiaries on overall profitability. While standalone revenue nearly doubled YoY (+85.67%), consolidated revenue grew at a more moderate 56.36%, indicating that existing subsidiary operations are maturing while new initiatives scale. The significant improvement in inventory management—showing negative changes in both standalone (-₹40.96 lakh) and consolidated (-₹40.96 lakh) statements—suggests improved supply chain efficiency or deliberate stock drawdown strategies that positively impacted current-quarter margins.

Chairman Laxmikant Kabra noted that the results reflect strong execution across business verticals. The company’s paid-up equity share capital remains unchanged at ₹1,434.59 lakh, with no new issuances during the quarter. Earnings per share (basic) increased to ₹0.91 from ₹0.66 YoY on a consolidated basis, offering shareholders tangible value creation despite macroeconomic uncertainties in the chemical sector.